Machado Patrick 4

What Happened Patrick Machado, a director of Arcus Biosciences (RCUS), received equity awards on June 11, 2026: 5,700 restricted stock units (RSUs) and a derivative award covering 16,900 shares (an option-like grant). Both awards were reported at $0.00 (typical for compensatory grants) and were recorded on the Form 4 filed June 12, 2026. These are grants (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (timely filing).
• Awards: 5,700 RSUs (grant) and 16,900 derivative shares (option-like grant), reported at $0.00.
• Shares owned after transaction: Not specified in this filing.
• Vesting notes (from footnotes):
  • RSUs: vest in full on the earlier of June 11, 2027 or the next annual meeting; accelerate to full vesting upon a change in control.
  • Derivative/option: vests in full on the earlier of June 11, 2027 or the next annual meeting; becomes fully vested and exercisable upon a change in control.
• No 10b5-1 plan, tax withholding, or late filing flags are indicated.

Context These grants are compensatory awards to a director and do not represent an open-market purchase (which some investors view as a stronger signal of personal conviction). RSUs convert to shares upon vesting; the derivative award appears to be an equity option or similar instrument that will vest and become exercisable per the schedule above. Accelerated vesting on a change in control is a common feature for retention and transition protections.